Biocodex

Biocodex, founded in 1923, is a multinational pharmaceutical company operating within the healthcare sector, with a specific focus on microbiota and neurology products. The company is globally recognized for its development of the probiotic yeast strain, Saccharomyces boulardii CNCM I-745. With a history spanning over six decades, Biocodex has transitioned from its French origins to become a significant international entity in the specialized field of microbiota research and therapeutics. Its commitment to innovation and quality underpins its mission to deliver effective healthcare solutions to a diverse global patient base. The company's operational scope includes a broad network of over 16 subsidiaries and more than 100 distribution partners worldwide, facilitating its extensive market reach.

The organization employs a workforce ranging from 1,000 to 5,000 individuals, contributing to its robust operational capacity and global presence. Biocodex's strategic approach involves continuous research and development to enhance its product portfolio and address unmet medical needs. The company's dedication to scientific advancement is evident in its specialized product lines, which aim to improve patient outcomes and well-being. For insights into the people driving these advancements, you can Meet Biocodex's team. This focus on human capital complements its technological and scientific endeavors, ensuring a comprehensive approach to pharmaceutical development and distribution.

Biocodex's product offerings are primarily categorized as pharmaceutical and therapeutic agents, designed to serve various health needs, including those specific to women's health. The company's business model encompasses both B2B and B2C strategies, reflecting its broad market engagement. Its revenue stands at $54.2M, supporting its extensive globalView more...